Significance of ten-valent pneumococcal conjugate vaccine SynflorixTM (PCV10) in the context of new efficacy data

Abstract

Clinical trial FinIP aimed to the onset of IPD in Finland has been still the first study confirming the effectiveness of PCV10 against IPD. The reported overall efficacy against vaccine and non-vaccine serotypes was 93% (95 % CI 75–99).

High efficacy of PCV10 against IPD in Finland is promising in terms of similar epidemiological situation concerning pneumococcal diseases in the Czech Republic.

Keywords

• pneumococcal vaccine
• SynflorixTM